8.4 Drug Administration & Therapy Management

8.4 Drug Administration & Therapy Management

Quick Answer: Minnesota’s practice definition separates (A) administration of drugs from (B) therapy management authority. Under §151.01, subd. 27(4), pharmacists participate in first-dose and emergency administration and IM/SC administration under a prescription drug order, plus regimen reviews. Clause (5) specially addresses IM/SC drugs used to treat mental illnesses under prescriber order (notify after administration) or protocol/CPA. Clause (7) governs initiation/management/modification/discontinuation of drug therapy under written protocol or CPA. Administration is not automatic license to redesign chronic regimens without a legal hook.

This section stitches together administration vignettes that MPJE items love—long-acting injectables, first-dose observation, emergency epinephrine-type scenarios, and “pharmacist adjusted therapy” fact patterns.

Administration Authorities in Clause (4)

§151.01, subd. 27(4) includes participation in:

• Drug and therapeutic device selection
• Drug administration for first dosage and medical emergencies
• Intramuscular and subcutaneous drug administration under a prescription drug order
• Drug regimen reviews
• Drug or drug-related research

First dosage and medical emergencies

“First dosage” and “medical emergencies” language supports pharmacist participation when a dose must be given in urgent or initial-dose contexts recognized by the practice definition. Exam stems often involve clinic/pharmacy sites prepared for anaphylaxis response during immunization or injectable therapy. The jurisprudence point is that administration in these contexts is inside the practice of pharmacy, not an unauthorized practice of medicine slogan—provided other legal requirements (order, protocol, training, facility policies, federal rules) are satisfied.

IM/SC under a prescription drug order

For general IM/SC administration under clause (4), the statute ties administration to a prescription drug order. That is different from:

• Vaccine administration under the specialized clause (6) framework
• Mental-illness IM/SC under the specialized clause (5) dual pathway
• Pharmacist-prescribed products under §151.37 that may also be administered when that subdivision authorizes administration (notably HIV-prevention drugs under subd. 17)

Order still matters for many injectables: a pharmacist is not free to invent a new IM antibiotic course without a valid order, protocol/CPA, or specific prescribing statute.

Mental-Illness IM/SC — Clause (5)

Clause (5) is a dedicated pathway for drug administration through intramuscular and subcutaneous administration used to treat mental illnesses, permitted under either:

Path A — Prescriber order + notice

• Administration occurs upon the order of a prescriber, and
• The prescriber is notified after administration is complete

Path B — Protocol or CPA

• Administration proceeds pursuant to a protocol or collaborative practice agreement as defined in subds. 27b and 27c, with initiation/management/modification/administration/discontinuation of drug therapy according to that protocol/CPA between the pharmacist and a dentist, optometrist, physician, PA, podiatrist, veterinarian, or APRN authorized under §148.235
• Any changes in drug therapy or medication administration made under the protocol/CPA must be documented in the patient’s medical record or reported to a practitioner responsible for the patient’s care

Exam contrast table:

Long-acting injectable antipsychotics are a classic real-world example of why clause (5) exists; answer with the legal pathway, not brand names.

Therapy Management — Clause (7) Revisited in Administration Context

Administration and therapy management overlap when a protocol says “give injection X and adjust schedule Y.” Clause (7) remains the general rule for initiation, management, modification, and discontinuation of drug therapy under written protocol/CPA with authorized practitioners.

Decision tree for stems:

1. Is the pharmacist only dispensing a practitioner’s Rx? → Ordinary practice rules (validity, DUR, counseling).
2. Is the pharmacist giving an injection already ordered? → Administration rules (clause (4) or (5) as applicable).
3. Is the pharmacist changing therapy (dose, agent, stop/start)? → Need protocol/CPA (clause (7)) or a specific §151.37 lane or another statute-specific protocol path (e.g., certain opiate-antagonist protocols).
4. Did therapy change occur? → Document or report.

CLIA-Waived Testing as a Therapy-Management Tool

Clause (3) again: pharmacists may order/perform CLIA-waived tests, collect specimens, interpret and notify, and refer. They may initiate, modify, or discontinue drug therapy only pursuant to protocol or CPA. Test administration may be delegated to technicians/interns under direct supervision.

Integrated vignette pattern: Pharmacist runs waived INR or glucose-style test → adjusts warfarin/insulin under CPA → documents in record or reports to practitioner. Remove the CPA and the same dose change becomes unauthorized therapy initiation/modification.

Opioid Antagonists and Public-Health Administration Paths

Beyond §151.37, subd. 16 pharmacist prescribing of antagonists for acute overdose, §151.01, subd. 27(11) allows participation in initiation, management, modification, and discontinuation of therapy with opiate antagonists (as defined in §604A.04, subd. 1) pursuant to:

1. A written protocol as allowed under clause (7); or
2. A written protocol with a community health board medical consultant or a practitioner designated by the commissioner of health, as allowed under §151.37, subd. 13

Administration and access pathways for responders under §151.37, subd. 12 and liability/access concepts under §604A.04 are typically tested with public-health/opioid chapters—but advanced-practice items may blend them. Identify whether the pharmacist is prescribing, protocol-managing, or enabling third-party administration.

Delegation, Supervision, and Professional Judgment

Advanced practice expands what pharmacists may do; it does not erase who must exercise judgment:

• Technicians remain non-judgment personnel (§151.01, subd. 15a); they may administer tests or vaccines only where statute expressly allows and conditions are met.
• Interns may prepare prescriptions for §151.37 products and participate in immunization when trained, but final prescribing approval and core professional determinations stay with the authorized pharmacist.
• PIC and supervising pharmacists remain responsible for systems that keep protocol binders current, training documented, and emergency response feasible.

If a stem shows a tech “deciding” to increase an injectable antipsychotic dose without a protocol pathway and without pharmacist judgment, that is unlawful practice structure—not efficient teamwork.

Putting the Advanced-Practice Chapter Together

Study Checklist

1. Separate administration from therapy change authority.
2. For mental-illness injectables, recite order + notify or protocol/CPA + document/report.
3. Require a written protocol/CPA for clause (7) management—not informal habit.
4. Keep CLIA-waived testing inside monitoring rules; therapy changes need protocol/CPA.
5. Know how opiate antagonist administration/prescribing paths differ.
6. Always ask: What written instrument or statute authorizes this act today?

Master these hooks and Area 2 advanced-practice items become pattern recognition rather than guesswork.